Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Transition Therapeutics Purchase Price Allocation (Details) (Details)

v3.6.0.2
Acquisitions, Investments, and Licenses - Transition Therapeutics Purchase Price Allocation (Details) (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Aug. 31, 2016
Dec. 31, 2015
Aug. 31, 2015
Dec. 31, 2014
Business Acquisition [Line Items]          
Goodwill $ 704,603   $ 743,348   $ 224,292
Transition Therapeutics, Inc.          
Business Acquisition [Line Items]          
Current assets        
Cash and cash equivalents       $ 15,878  
Goodwill   $ 3,453      
Other assets   634      
Accounts payable and other liabilities   (1,035)      
Deferred tax liability   (1,400)      
Total purchase price   58,530      
In Process Research and Development | Transition Therapeutics, Inc.          
Business Acquisition [Line Items]          
IPR&D assets   $ 41,000